Sodium Iodide [131I] Diagnostic Capsules GE Healthcare 3.7 MBq 挪威 - 挪威文 - Statens legemiddelverk

sodium iodide [131i] diagnostic capsules ge healthcare 3.7 mbq

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq

Thallous (201TI) Chloride 37 MBq/ ml 挪威 - 挪威文 - Statens legemiddelverk

thallous (201ti) chloride 37 mbq/ ml

curium netherlands b.v. - talliumklorid (201tl) - injeksjonsvæske, oppløsning - 37 mbq/ ml

TechneScan DMSA 1.2 mg 挪威 - 挪威文 - Statens legemiddelverk

technescan dmsa 1.2 mg

curium netherlands b.v. - dimerkaptosuccininsyre - preparasjonssett til radioaktive legemidler - 1.2 mg

Nanocis 0.15 mg 挪威 - 挪威文 - Statens legemiddelverk

nanocis 0.15 mg

cis bio international - rheniumsulfid - injeksjonsvæske, oppløsning - 0.15 mg

Tecfidera 240 mg 挪威 - 挪威文 - Statens legemiddelverk

tecfidera 240 mg

2care4 aps - dimetylfumarat - enterokapsel, hard - 240 mg

Tecfidera 240 mg 挪威 - 挪威文 - Statens legemiddelverk

tecfidera 240 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 240 mg

Tecfidera 120 mg 挪威 - 挪威文 - Statens legemiddelverk

tecfidera 120 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 120 mg

Pantoprazol Oresund Pharma 40 mg 挪威 - 挪威文 - Statens legemiddelverk

pantoprazol oresund pharma 40 mg

oresund pharma aps - pantoprazolnatriumsesquihydrat - pulver til injeksjonsvæske, oppløsning - 40 mg

Somac 40 mg 挪威 - 挪威文 - Statens legemiddelverk

somac 40 mg

orifarm as - pantoprazolnatriumsesquihydrat - pulver til injeksjonsvæske, oppløsning - 40 mg

Tyruko 欧盟 - 挪威文 - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressive - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.